Embryonal cardiac muscle cells, their preparation and their use
Patent 5928943 Issued on July 27, 1999. Estimated Expiration Date: 
August 22, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 22, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssigneeApplicationNo. 849706 filed on 08/22/1997US Classes:435/363, Primate cell, per se435/29, Involving viable micro-organism435/34, Determining presence or kind of micro-organism; use of selective media435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/366, Human435/375Method of regulating cell metabolism or physiologyExaminersPrimary: Degen, NancyAttorney, Agent or FirmForeign Patent References
International ClassesC12N 005/06C12N 005/10 C12N 005/16 C12Q 001/02 Foreign Application Priority Data1994-11-22 DEAbstractThe invention concerns embryonal (cardiomyocytary and cardiomyoblastary) cardiac muscle cells, their preparation and their use, in particular for cell-mediated gene transplant. The areas of application of the invention are medicine and genetic engineering. The embryonal cardiac muscle cells according to the invention contain two gene constructs comprising: a) a regulatory, 1.2-kb long DNA sequence of the ventricle-specific myosin light-chain-2 (MLC-2v) promoter, the selectable marker gene ଲ-galactosidase in fusion with the reporter gene neomycin; and b) a regulatory DNA sequence of the herpes simplex virus thymidine kinase promoter and the selectable marker gene hygromycin, and optionally immortalizing genes and/or optionally genes inactivated by homologous recombination and/or optionally one or a plurality of therapeutic genes. The cells can advantageously be used for cell-mediated gene transplant, in particular for constructing healthy tissue and assisting contractile functions, for investigating substances, in particular for pharmacological investigations and for the transfer of therapeutic genes into the myocardium.Other References
Field of SearchANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFOREInvolving viable micro-organism Primate cell, per se Determining presence or kind of micro-organism; use of selective media Human Method of regulating cell metabolism or physiology Polynucleotide (e.g., RNA, DNA, etc.) |
| ||||||||||||||
